The long way of biomarkers: from bench to bedside.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

3 citing papers in PubMed.

1. Progress in the study of pentraxin-3(PTX-3) as a biomarker for sepsis.Frontiers in medicine · 2024
   Review
2. Plasma thioredoxin levels during post-cardiac arrest syndrome: relationship with severity and outcome.Critical care (London, England) · 2013
   Article
3. Year in review in Intensive Care Medicine 2010: I. Acute renal failure, outcome, risk assessment and ICU performance, sepsis, neuro intensive care and experimentals.Intensive care medicine · 2011
   Article

Corrections and comments

• Comment on
  PTX3 as a potential biomarker of acute lung injury: supporting evidence from animal experimentation.2010
• Comment on
  Persisting high levels of plasma pentraxin 3 over the first days after severe sepsis and septic shock onset are associated with mortality.2010

Authors and funding

3 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as